Ashland Inc (NYSE: ASH) has reported E.P.S. of $-0.15 for its fourth fiscal quarter (ending September 30) versus $1.13 for the same period a year ago — a decline of -113%. Relative to the consensus […]
For its third fiscal quarter (ending September 30), Ligand Pharmaceuticals Inc (NASDAQ: LGND) has reported a -154% decline in E.P.S. from $1.37 a year ago to $-0.74 in the current quarter. This performance was $-1.36 […]
For its third fiscal quarter (ending September 30), Full House Resorts Inc (NASDAQ: FLL) has reported E.P.S. of $0.13 compared to $-0.10 a year ago. For the latest four quarters through September 30, E.P.S. were […]
BK Technologies Corp (NYSEAMERICAN: BKTI) stock closed at $14.19 on 11/8/23 after a major increase of 10.3%. The stock has risen 12.6% during the last week but has been weak relative to the market over […]
Cryoport Inc (NASDAQ: CYRX) has reported E.P.S. of $-0.31 for its third fiscal quarter (ending September 30) versus $-0.15 for the same period a year ago. This performance was $-0.02 short of the consensus estimate […]
Natera Inc (NASDAQ: NTRA) has reported E.P.S. of $-0.95 for its third fiscal quarter (ending September 30) versus $-1.25 for the same period a year ago. Relative to the consensus estimate of $-0.97, this was […]
For its third fiscal quarter (ending September 30), Ceva Inc (NASDAQ: CEVA) has reported E.P.S. of $-0.12 compared to $-0.89 a year ago. This performance was $-0.16 short of the consensus estimate of $0.04. E.P.S. […]
Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported a loss for its third fiscal quarter (ending September 30) of $-0.73 versus a loss $-0.57 for the same period a year ago. This result exceeded the consensus […]
Zevra Therapeutics Inc (NASDAQ: ZVRA) has reported a loss for its third fiscal quarter (ending September 30) of $-0.40 versus a loss $-0.19 for the same period a year ago. This result fell short of […]
For its third fiscal quarter (ending September 30), Waters Corp (NYSE: WAT) has reported a -13% decline in E.P.S. from $2.61 a year ago to $2.28 in the current quarter. This result fell short of […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research